The medical inhibition of the VEGF/VEGFR pathway failed to prolong overall survival in patients with glioblastoma [162, 163], and studies demonstrated that circulating Ang-2 levels rebounded after the administration of the pan-VEGFR inhibitor cediranib [164]. This evidence concerns the gene KDR and glioblastoma.